Bibliografía del artículo
1. World Health Organization. WHO Factsheet Number 310: The 10 leading causes of death by broad income Group (2004). Geneva, World Health Organization, 2008.
2. World Health Organization. Global Tuberculosis Control: surveillance, planning, financing: WHO Report 2008, Geneva. World Health Organization, 2008.
3. Edlin BR, Tokars JL, Grieco MH y col. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New Eng J Med 326:1514-21, 1992.
4. Breathnach AS, De Ruiter A, Holdsworth GM, y col. An outbreak of multidrug-Resistant tuberculosis in a London teaching hospital. J Hosp Infect 39:111-17, 1998.
5. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33:1085-1094, 2009.
6. Zignol M, Hosseini MR, Wright A, y col. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194:479-85, 2006.
7. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Weekly Epidemiol Record 81:430-32, 2006.
8. Gandhi NR, Moll A, Sturm AW, y col. Extensively drug-resistant tuberculosis as a cause of death in a patient coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-80, 2006.
9. Mitnick CD, Shin SS, Seung KJ, y col. Comprehensive treatment of extensively drug-resistant tuberculosis. N Eng J Med 359:563-74, 2008.
10. Centers for Diseases Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs world-wide. MMWR Morb Mort Wkly Rep 55:301-05, 2006.
11. Blass SH, Mutterlein R, Weig J, y col. Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 8:60-67, 2008.
12. Velayati AA, Masjedi MR, Farnia P, y col. Emergenge of new forms of totally drug-resistant tuberculosis bacilli. Chest 136:420-25, 2009.
13. Laserson KP, Thorpe LE, Leimane V, y col. Speaking the same language: treatment outcomes definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9:640-45, 2005.
14. Siddigi SH, Libonati JP, Middlebrook G. Evaluation of a rapid radiometric for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 13:908-12, 1981.
15. Wayne LG. Simple pyrazinamidasa and ureasa test for routine identificaction of Mycobactaria. Am Rev Respir Dis 109:147-31, 1974.
16. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacilli tuberculleux aux drogues antibacillaires pour la méthode des proportions. Rev de Tuberculose 27:217-72, 1963.
17. Guidelines for drug susceptibility testing for second line anti tuberculosis drugs for DOTS-PLUS. WHO/CDS/TB 2001.288.
18. Van Embden JDA, Cave MD, Crawford JT, y col. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting : recommendations for a standardized methodology. J Clin Microbiol 31:406-09, 1993.
19. Ritacco V, Di Lonardo M, Reniero A, y col. Nosocomial spread of HIV-related Multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 176:637-42, 1997.
20. Raviglione MC, Smith IM. XDR tuberculosis. Implications for global public health. N Engl J Med 356:1554-56, 2007.
21. Van Rie A, Enarson D. XDR tuberculosis: an indicator of public health negligent. Lancet 368:1554-56, 2006.
22. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis 7:443, 2007.
23. Van Helden PD, Victor T, Warren RM. The "source" of drug resistant TB outbreaks (letter). Science 314:419-20, 2006.
24. Mukherjee J, Rich ML, Socci AR, y col. Programmes and principles in treatment of Multidrug-resistant tuberculosis. Lancet 363:474-81, 2004.
25. Shah NS, Wright A, Bai GH, y col. Worldwide emergence of extensively drug- resistant tuberculosis. Emerg Infect Dis 13:380-87, 2007.
26. Ballow CH, Jones RN, Biedenbach DJ, y col. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 43:75-83, 2002.
27. Alcalá L, Ruiz-Serrano MJ, Pérez Fernández Turégano C, y col. In vitro activities of linezolid against clinical isolates of Mycobaterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47:416-17, 2003.
28. Fortun J, Martin-Davila P, Navas E, y col. Linezolid for the treatment of multidrug- Resistant tuberculosis. J Antimicrob Chemoter 56:180-85, 2005.
29. Valencia ME, Moreno V, Laguna F, y col. Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities? Enferm Infecc Microbiol Clin 19:37-39, 2001.
30. World Health Organization. Guidelines for the programmatic management of drug- resistant tuberculosis. WHO/HTM/TB/2006.361. Emergency update 2008. Executive summary (leaflet available requesting to: tbdocs@who.int).
31. Abbate E, Brea A, Cufré M, y col. Linezolid in multidrug-resistant tuberculosis treatment. Eur Respir J 24(Supppl.48):485s, 2004.
32. Abbate E, Brea A, Cufré M, y col. Linezolid en el tratamiento de tuberculosis multirresistente. Archiv Bronconeum; 40(Suppl.4): 26, 2004.
33. Gerson SL, Kaplan SL, Bruss JB, y col. Hematologic effects of linezolid: summary of clinical experience. Antimicrb Agents Chemother 46:2723-26, 2002.
34. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 285:1291, 2001.
35. Acha V, Zaragueta M, Martinez Y, y col. Linezolid induced anemia. Enferm Infecc Microbiol Clin 21:321-22, 2003.
36. Bressler AM, Zimmer SM, Gilmore JL, y col. Peripheral neuropathy associated with prolonged used of linezolid. Lancet Infec Dis 4:528-31, 2004.
37. Lee E, Burger S, Shah J, y col. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 37:1389-91, 2003.
38. Migliori GB, Eker B, Richardson MD, y col. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34:387-93, 2009.
39. Schecter GF, Scott C, True L, y col. Linezolid in the treatment of multidrug- resistant tuberculosis. Clin Infect Dis 50:49-55, 2010.
40. Condos R, Hadgiangelis N, Leibert E, y col. Case series report of a linezolid- containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-92, 2008.
41. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR-and XDR-TB: an Indian perspective (letter). Eur Respir J 35:936-38, 2010.
42. Migliori GB, Eker B, Richardson MD y col. (Letter response). Eur Respir J 35:938-40, 2010.
43. Koh WJ, Kwon OJ, Gwak H, y col. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64:388-91, 2009.
44. Lienhardt Ch, Vernon A, Raviglione MC. New drugs regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16:186-93, 2010.
45. Gillespie SH, Kennedy N. Fluoroquinolones a new treatment for tuberculosis. Int J Tuberc Lung Dis 2:265-71, 1998.
46. Rodríguez JC, Ruiz M, Climent A, y col. In Vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17:229-31, 2001.
47. Ji B, Lounis N, Maslo C, y col. In vitro and in vivo activities of moxifloxacin and clinafoxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:2066-69, 1998.
48. Hu Y, Coates AR, Mitchinson DA. Sterilizing activity of fluoroquinolones against Rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:653-57, 2003.
49. Devasia RA, Blackman A, Gebretsadik T, y col. Fluoroquinolone resistance in Mycobacterium tuberculosis. Am J Respir Crit Care Med 180:365-70, 2009.
50. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 40:319-27, 1997.
51. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multi-drug resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16:69-71, 2000.
52. Amaral L, Viveiros M, Kristiansen JE. Non antibiotics: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 7:887-91, 2006.
53. Thacoody HKR. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 64:566-574.
54. The WHO/IUATLD Global Project on antituberculosis drug resistance surveillance Anti-tuberculosis drug resistance in the world. Fourth Global Report. WHO/ HTM/TB 2008.394.
55. Abbate E, Vescovo M, Natiello M, y col. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos. Rev Arg Med Respir 7:19-25, 2007.